CytomX Therapeutics opened higher at $2.15, compared with its previous close of $2.13. In the last trading session, the stock traded between $2.04 and $2.18. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in CytomX Therapeutics is now worth
$ 29.03
Resulting in a loss of
$ 70.97 (70.97%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.10 (-4.46%)
Day High
$2.18
Day Low
$2.04
Day Open
$2.15
Prev Close
$2.13
Volume
24,62,598
1W Return
-13.48%
1M Return
-16.08%
3M Return
-40.93%
6M Return
-47.28%
1Y Return
-50.37%
Fundamentals
Market Cap ($ Mn)
444
PE Ratio
-
PB Ratio
2.32
PEG Ratio
-
ROE
-24.75%
ROCE
-25.32%
EPS (TTM)
$-0.09
Investment Returns
1 Week
-13.48%
1 Month
-16.08%
3 Months
-40.93%
6 Months
-47.28%
9 Months
-63.40%
Financials
Quarterly
All values in $ Mn
50.9
Mar 25
18.7
Jun 25
6.0
Sep 25
0.7
Dec 25
1.4
Jun 26
1.7
Sep 26
Updates
12Nov
JP Morgan raises CytomX Therapeutics price target to $12
JP Morgan maintains Overweight rating on CytomX Therapeutics. Price target raised from $11 to $12 by analyst Anupam Rama. Wedbush previously raised target to $12 with Outperform rating. Two major firms now align on $12 valuation outlook.
Today
6Nov
CytomX Therapeutics Q3FY26 Results: Revenue falls to $1.7M, cash at $348M
Revenue fell to $1.7 million from $6 million YoY due to Astellas collaboration end. Cash position increased to $348 million, including $37 million from Regeneron. Operating expenses rose 16% to $25.2 million driven by personnel and consulting. Registrational study for Varseta M planned for first half of 2027. Cash runway extended into second half of 2028.
7 days ago
7Aug
CytomX Therapeutics secures $37M from Regeneron amid Q2 revenue miss
CytomX Therapeutics announced Q2 2026 financials, reporting $1.4 million in revenue and a net loss of $20.666 million. The company secured $37.0 million from Regeneron, boosting cash reserves to $330.3 million. Pipeline updates include completed enrollment for Varseta-M Phase 1 CRC trials and upcoming expansion into other GI cancers.
3mo ago
3Aug
CytomX Therapeutics appoints Alejandra Carvajal as chief legal officer
CytomX Therapeutics appoints Alejandra Carvajal as Chief Legal Officer to lead legal strategy for its PROBODY pipeline. Carvajal joins from Mersana Therapeutics, bringing extensive experience in biotech M&A and regulatory compliance. The move supports CytomX's clinical advancement of Varseta-M and CX-801.
